IMPAX CV OUTBOUND (RESULTS MANAGEMENT 2.08)
Report
- Report Number
- 1225058-2014-00234
- Event Type
- Malfunction
- Date Received
- February 28, 2014
- Date of Event
- February 14, 2014
- Report Date
- February 14, 2014
- Manufacturer
- AGFA HEALTHCARE CORP
- Product Code
- LLZ
- PMA / PMN Number
- K050858
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FL, US
- Reporter Occupation
- OTHER
Narratives
EVAL SUMMARY: AGFA IS CURRENTLY REVIEWING THE RMAT LOGS TO IDENTIFY WHEN THE CUSTOMIZATION CHANGE WAS INTRODUCED INTO THE PRODUCTION ENVIRONMENT. (B)(4). AGFA'S CLINICAL ANALYST ALSO DETERMINED FROM A STUDY SELECTED FROM THE POTENTIALLY AFFECTED RMAT LOG, THAT THE INCORRECT SENTENCE FINDING LINE WAS LOCATED DIRECTLY ABOVE THE ACTUAL MEASUREMENTS (WHICH ARE CORRECT) AND THAT A USER WOULD BE MORE LIKELY TO LOOK AT THE ACTUAL MEASUREMENTS IN A REPORT TO FORMULATE CONCLUSIONS AND TREATMENT DECISIONS; AN INCLINATION AS TO WHY THE READING PHYSICIANS MISSED THE INCORRECT SENTENCE FINDING OF "HYPOTENSION" VERSUS "HYPERTENSION" IN THE MANY PREVIOUS PULMONARY ARTERY PATHOLOGY REPORTS. A REPORTABLE CORRECTION IS UNDERWAY FOR THIS ISSUE AND HAS BEEN REPORTED TO THE FDA. FDA REFERENCE# IS Z-2112-10. ANY FURTHER INVESTIGATION FOR THE SITE DESCRIBED IN THIS REPORT WILL BE DOCUMENTED IN THE ONGOING CFR PART 806 REPORTING. (B)(4).
AGFA SUBMITTED MDR REPORT# 1225058-2010-00001 TO THE FDA ON JUNE 7, 2010 FOR A SITE IN THE US. A 7TH OCCURRENCE IS BEING REPORTED FOR THE SAME ISSUE/SAME DEVICE: IMPAX CV RESULTS MANAGEMENT ADMINISTRATION TOOL (RMAT). THE CUSTOMER, THE INITIAL REPORTER, IN THIS NEW EVENT CONTACTED AGFA ON FEBRUARY 14, 2014 AND REPORTED A READING PHYSICIAN HAD DISCOVERED AN INCORRECT STATEMENT IN THE PULMONARY ARTERY FINDINGS WITHIN THEIR RMAT REPORTING. THE CUSTOMER CONFIRMED THERE WERE NO REPORTS OF PATIENT HARM DURING THIS EVENT. THE CUSTOMER STATED NO RMAT CUSTOMIZATION REQUESTS HAD BEEN MADE TO AGFA, AND THE SITE'S SUPER USER HAD NOT MADE ANY CUSTOM CHANGES TO THE PULMONARY ARTERY FINDINGS WITHIN THE REPORTING TOOL, ABIDING BY AGFA'S RMAT TERMS OF USE. THE CUSTOMER DESCRIBED WHEN REPORTS WERE CREATED FOR TRANS ESOPHAGEAL ECHOCARDIOGRAM (TEE), TRANSTHORACIC ECHOCARDIOGRAM (TTE) AND STRESS (STR) STUDIES, AND WHEN THE END-USER SELECTED THE "MILD TO MODERATE" RADIO BUTTON IN THE PULMONARY ARTERY PATHOLOGY SECTION, THE INCORRECT SENTENCE FINDING OF "THERE IS MILD TO MODERATE PULMONARY HYPOTENSION" WAS GENERATED IN THE REPORT. THE SENTENCE FINDING SHOULD READ "THERE IS MILD TO MODERATE PULMONARY HYPERTENSION." THE SAME DAY THE CUSTOMER REPORTED THE EVENT, AGFA CORRECTED THE STATEMENT IN BOTH THE TEST AND PRODUCTION ENVIRONMENTS AND; IN TURN, THE CUSTOMER REVIEWED THE CORRECTION AND CONFIRMED THE STATEMENT WAS READING CORRECTLY WITH "HYPERTENSION" VERSUS "HYPOTENSION". AGFA CONFIRMED RMAT SUPER USER WAS DISABLED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 125557 | IMPAX CV OUTBOUND (RESULTS MANAGEMENT 2.08) | PICTURE ARCHIVING AND COMMUNICATION | LLZ | AGFA HEALTHCARE CORP | IMPZX CV RM 2.08 | NA |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |